Cystic fibrosis (CF) liver disease (CFLD), a leading cause of death in CF, is mostly described in pediatric populations. Adult-onset CFLD lacks sufficient characterization and diagnostic tools. A cohort of CF patients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers. Historical CFLD diagnostic criteria were compared with newly proposed CFLD criteria. Thirty-six CF patients were followed for a median of 24.5 years (interquartile range 15.6-32.9). By the last follow-up, 11 (31%) had died. With conventional criteria, 8 (22%) patients had CFLD; and by the new criteria, 17 (47%) had CFLD at a median age of 36.6 years (interquartile range 26.5-43.2). By the new criteria, those with CFLD had higher median alanine aminotransferase (42 versus 27, P 5 0.005), aspartate aminotransferase (AST; 26 versus 21, P 5 0.01), direct bilirubin (0.13 versus 0.1, P 5 0.01), prothrombin time (14.4 versus 12.4, P 5 0.002), and AST-to-platelet ratio index (0.31 versus 0.23, P 5 0.003) over the last 2 years of follow-up. Subjects with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P 5 0.02), AST (35 versus 25U/L, P 5 0.02), AST-to-platelet ratio index (0.77 versus 0.25, P 5 0.0004), and Fibrosis-4 index (2.14 versus 0.74, P 5 0.0003) and lower platelet counts (205 versus 293, P 5 0.02). One CFLD patient had nodular regenerative hyperplasia. Longitudinally, mean platelet counts significantly declined in the CFLD group (from 310 to 230 U/L, P 5 0.0005). Deceased CFLD patients had lower platelet counts than those alive with CFLD (143 versus 258 U/L, P 5 0.004) or those deceased with no CFLD (143 versus 327U/L, P 5 0.006). Conclusion: Adult-onset CFLD may be more prevalent than previously described, which suggests a later wave of CFLD that impacts morbidity; routine liver tests, radiologic imaging, noninvasive fibrosis markers, and FibroScan can be used algorithmically to identify adult CFLD; and further evaluation in other CF cohorts should be performed for validation. (HEPATOLOGY 2017;66:591-601).
C ystic fibrosis (CF) is the most common autosomal recessive genetic disorder in Caucasians of European descent (1, 2) with an annual incidence of 1 in 3,500 live births. (3) This disease results from a genetic mutation that codes for the CF transmembrane conductance regulator protein, which plays an important role in chloride transport across epithelial membranes. The DF508 gene mutation is the most common cause of CF in North America (3, 4) ; however, more than 1,300 known gene mutations have been associated with this disease. As a result of increased awareness and improved therapies, the median survival in patients with CF has improved to 37 years compared to 16 years in 1970. (3) Abbreviations: AAR, AST-to-ALT ratio; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; CF, cystic fibrosis; CFLD, CF liver disease; FIB-4, Fibrosis-4 index; GGT, gamma-glutamyltransferase; IQR, interquartile range; NIH, National Institutes of Health; NRH, nodular regenerative hyperplasia; PT, prothrombin time; VCTE, vibration controlled transient elastography.
In CF, cystic fibrosis liver disease (CFLD) is the third leading cause of mortality and is estimated to account for 2.5%-5% of overall CF mortality. (1, 5, 6) While pediatric CFLD is well described with prevalence rates of up to 25% of children, (3, (6) (7) (8) (9) adult-onset CFLD has not been adequately characterized, resulting in highly variable prevalence rates, ranging from 2%-37%. (3, 4, 10) The onset of liver disease in adults is a relatively newer finding in CF and may be a result of improved survival rates along with inconsistent definitions of CFLD. (9, 11, 12) Although general agreement exists around the clinical utility of screening for CFLD, no single reliable physical, biochemical, or radiological screening tool is available. (13) Unlike other diseases with potential liver involvement, the utility of the "gold standard" liver biopsy has been described as "inconsistent" in diagnosing CFLD or has resulted in inadequate staging of CFLD, which may be a result of the various liver diseases that have been associated with CF. (6, 14) Thus, the field has generally used composite criteria for the diagnosis of CFLD by employing multiple tools including physical examination as well as biochemical and imaging modalities. (12) More recently, noninvasive liver fibrosis markers have demonstrated promise in assisting in the diagnosis of CFLD. (11, 15, 16) In this study, we aimed to expand on the description of adult CFLD using data from a cohort of patients with CF who have been followed at the National Institutes of Health (NIH) Clinical Center for up to 38 years, to evaluate the utility of noninvasive markers of liver disease in adult CFLD and to develop a scoring system that can assist in diagnosing adult CFLD using a combination of routine liver tests, radiologic imaging, and noninvasive markers of hepatic fibrosis.
Patients and Methods

PATIENTS
A cohort of genetically confirmed CF patients followed prospectively in a natural history protocol at the NIH Clinical Center was evaluated (NCT00001223 and NCT0001971). Longitudinal demographic, clinical, radiographic, and laboratory data were collected. CF patients with suspected liver disease were referred for hepatology evaluation. Reasons for referral included persistently abnormal liver tests, evidence of viral hepatitis, and abnormal hepatic imaging. Patients were evaluated by one of three hepatologists (C.K., J.H.H., T.H.) with history, physical examination, radiologic imaging, laboratory investigations, and transient elastography (available beginning in 2007). All patients underwent serologic testing for chronic liver diseases including viral hepatitis, autoimmune hepatitis, Wilson disease, alpha-1-antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis. Secondary sclerosing cholangitis was not an exclusion for the diagnosis of CFLD. If clinically indicated, patients were offered liver biopsy. All coauthors had access to the data and reviewed and approved the final manuscript.
EVALUATION OF EXISTING AND NEW DIAGNOSTIC CRITERIA FOR ADULT CFLD
The diagnostic criteria for CFLD described by Debray et al. were evaluated in this cohort of CF patients. (12) The specifics of these criteria are described in an earlier publication by Debray and colleagues and can also be found in Table 1 . (12) For the purposes of this study, these diagnostic criteria will be designated as the "Debray criteria" hereafter. In brief, these criteria suggest that the diagnosis of CFLD should be considered if significant findings are identified in at least two of the four categories including the physical examination, liver function tests, ultrasonography, and liver biopsy.
In addition to evaluating this cohort of CF patients with the Debray criteria for CFLD, a new set of criteria was developed and evaluated based on expanding evidence of the utility of noninvasive biomarkers in CFLD ( Both the Debray criteria and the new criteria were employed at baseline to demonstrate the presence or absence of CFLD at baseline. Subjects were then followed longitudinally with at least one visit annually. Based on the assessments performed during these visits (biochemical and radiological), subjects were identified as developing CFLD when they demonstrated abnormal values that fulfilled the Debray criteria and/or the new criteria with abnormal measurements on multiple dates over a 2-year period.
Normal values for ALT, AST, ALP, and GGT were based on the cutoffs for the assays used by the NIH Clinical Center laboratory. Adult patients with liver and spleen spans greater than 12 cm and 13 cm were considered to have hepatomegaly and splenomegaly, respectively. (12) In the evaluation of noninvasive fibrosis markers, the APRI, FIB-4, and AAR were calculated (see Supporting Information for formulas) and used as they have been extensively evaluated and validated in chronic hepatitis C with additional demonstrations of utility in chronic hepatitis B and nonalcoholic steatohepatitis. Specifically, use of the APRI and FIB-4 is currently incorporated into practice guidelines for the management of chronic hepatitis C. (17) In the APRI, a cutoff value of 0.50 was used for discerning the absence of significant fibrosis based on the seminal publication by Wai et al. (17, 18) In the FIB-4 index, a cutoff value of 3.25 was used for the detection of advanced fibrosis as described by Sterling et al. in the seminal study evaluating subjects with human immunodeficiency virus/hepatitis C virus coinfection. (17, 19) For the AAR, a cutoff value 1 has been predictive of cirrhosis in chronic viral hepatitis and nonalcoholic steatohepatitis. (20) (21) (22) VCTE, measured by FibroScan, was evaluated in patients after 2007, with informed consent. (23) Individuals specifically trained in the technique performed the elastography. At least 10 determinations were made, and median results were expressed in kilopascals. A liver stiffness score of >6.8 kPa was used as the cutoff for liver disease based on a study by Kitson et al., which demonstrated 76% sensitivity and 92% specificity for CFLD. (11) 
STATISTICAL ANALYSIS
Statistical analysis was performed using JMP (version 10; SAS Inc., Cary, NC; Microsoft Excel [2011] for Mac OS X and Prism GraphPad version 6 for Mac OS X, GraphPad Software, La Jolla, CA). Summary statistics of baseline data were presented as frequencies and median with interquartile range (IQR), unless specified otherwise. Two-sided Fisher's exact tests were used to compare categorical group characteristics.
Comparison of biomarkers between groups at baseline, end of follow-up, and with VCTE was performed using the Mann-Whitney test. Paired comparison of biomarkers over the first 2 years of follow-up and the last 2 years of follow-up was performed by the Wilcoxon signed-rank test. Statistical analysis of mortality and platelet counts were conducted by the MannWhitney test. P < 0.05 was considered to be statistically significant.
Results
SUBJECT DEMOGRAPHICS
Forty adult patients with CF were evaluated, and 4 were excluded due to inadequate duration of follow-up (Fig. 1) . The remaining 36 patients were followed beginning at a median age of 11 years for a median of 24.5 years (IQR 15.6-32.9), with baseline demographics shown in Table 2 . No subjects had evidence of liver disease during the first 2 years of follow-up by routine liver tests, radiologic imaging, or noninvasive fibrosis markers. Twenty-six of 27 patients with known genotypes had class I-III functional mutations of the CF transmembrane conductance regulator allele. Groups with and without CFLD by the new criteria were relatively well matched without differences in the duration of follow-up, median age at diagnosis, and age at enrollment. Twenty-five patients were alive at the end of the study period, with 11 deaths occurring at ages 24-66 from respiratory failure (n 5 3), infection (n 5 3), lung transplant (n 5 2), complications of decompensated liver disease with portal hypertension, ascites, and variceal bleeding (n 5 2), and accidental causes (n 5 1). During the course of the study period, one patient underwent a transjugular liver biopsy with hepatic venous pressure gradient measurements, which revealed focal biliary cirrhosis and nodular regenerative hyperplasia (NRH) with a hepatic venous pressure gradient of 12 mm Hg (Supporting Fig. S1 ). Seven of 17 subjects with CFLD were placed on ursodeoxycholic acid treatment after diagnosis of CFLD.
COMPARISON BETWEEN THOSE CLASSIFIED AS HAVING CFLD AND NO CFLD BY THE DEBRAY CRITERIA
Based on the original criteria presented by Debray et al., 8 (22%) patients met the criteria for adult CFLD (Tables 1 and 3 ). While there were no differences in sex between groups (88% versus 67% male, P 5 0.40), more subjects with CFLD were homozygous for DF508 (P 5 0.04) compared to those without CFLD. The median age at CFLD diagnosis was 34.8 years (IQR 29.7-39.4), and there were 3 deaths in the CFLD group and 8 deaths in the group without CFLD by the end of the study period.
During the first 2 years of follow-up, there were no significant differences between those with and without CFLD comparing routine liver tests, platelet counts, prothrombin time (PT), and noninvasive markers of fibrosis (Table 3) . However, albumin levels demonstrated a trend toward lower values in the CFLD group compared to the no CFLD group (3.9 versus 4.1, P 5 0.05). In the last 2 years of follow-up, total bilirubin (0.6 versus 0.38, P 5 0.08) and direct bilirubin (0.18 versus 0.1, P 5 0.06) trended toward higher values in In a longitudinal comparison, the mean platelet counts from the first 2 years were compared with the last 2 years of follow-up between the CFLD and no CFLD groups. The CFLD group demonstrated a significant decline in mean platelet counts from 336 U/L to 217 U/L (P 5 0.02), whereas the no CFLD group did not demonstrate a significant decline by the end of follow-up (from 330 U/L to 271 U/L, P 5 0.08).
COMPARISON BETWEEN THOSE WITH CFLD AND WITHOUT CFLD BY THE NEW CRITERIA
Based on the aforementioned new CFLD criteria, 17 (47%) patients met the criteria for CFLD (Tables 1  and 2 ). There was a trend toward more male patients having CFLD compared to those without CFLD (88% versus 58%, P 5 0.06) without significant differences in homozygosity for DF508 (P 5 0.67). The median age at diagnosis of CFLD was 36.6 years (IQR 26.5-43.2), and there were 4 deaths in the CFLD group and 7 deaths in the group without CFLD. In comparing the age at diagnosis of the same 8 subjects diagnosed by the Debray criteria and the new criteria, although the median age at diagnosis was younger by 5.4 years, this was not statistically significant (P 5 0.37). By log-rank test, more CF patients were diagnosed with liver disease using the new criteria and at earlier times compared to the Debray criteria (P 5 0.017) (Fig. 2) .
During the first 2 years of follow-up, median liver tests (AST, ALT, ALP, total and direct bilirubin) were within normal limits, as were platelet counts, PT, and albumin, without significant differences between the CFLD and non-CFLD groups (Table 4) . Additionally, noninvasive fibrosis biomarkers (APRI, FIB-4, and AAR) were within normal limits without differences between groups.
During the final 2 years of follow-up, significant differences were identified in certain biochemical parameters between the two groups ( Table 4 ). The adult CFLD group had significantly higher AST (26 versus 21, P 5 0.01), ALT (42 versus 27 U/L, P 5 0.005), direct bilirubin (0.13 versus 0.10 mg/dL, P 5 0.01), and PT (14.4 versus 12.4 seconds, P 5 0.002). However, there were no significant differences in ALP, total bilirubin, platelets, and albumin. In comparing changes in the noninvasive fibrosis biomarkers, APRI was significantly higher in the CFLD group (0.34 versus 0.20, P 5 0.003) and FIB-4 demonstrated a trend toward higher values in the CFLD group (0.78 versus 0.70, P 5 0.08). However, there was no difference in the AAR between groups.
VCTE IN CFLD
VCTE was performed in 24 adult subjects with CF, and no differences were identified in comparing subjects with and without CFLD (5.4 versus 4 kPa, P 5 0.34). However, platelet counts were strongly correlated with VCTE (Spearman's r, -0.60; P 5 0.002). When comparing subjects with a normal FibroScan (6.8 kPa) and subjects with an abnormal FibroScan (>6.8 kPa) with biomarkers of liver disease, significant differences were identified. Interestingly, subjects with a FibroScan >6.8 kPa had significantly higher mean ALT levels (42. P 5 0.02) (Fig. 3) . Additionally, the APRI was significantly higher in subjects with a FibroScan score >6.8 kPa (0.77 versus 0.25, P 5 0.0004), as was FIB-4 (2.14 versus 0.74, P 5 0.0003) (Fig. 3) but not AAR (1.01 versus 0.57, P 5 0.13). No significant associations were identified with other biomarkers of liver disease including PT or bilirubin.
LONGITUDINAL FOLLOW-UP OF PATIENTS WITH AND WITHOUT CFLD BY THE NEW CRITERIA
Because declining platelet counts have been used as a marker of progressive liver disease and associated with poor outcomes, (24, 25) platelet counts were evaluated in a longitudinal fashion in the CF cohort. First, the mean platelet counts during the first 2 years of follow-up and the last 2 years of follow-up were compared in subjects with and without CFLD by the new criteria. Subjects with CFLD demonstrated a significant decline in mean platelets over the follow-up period (from 310 to 230 U/L, P 5 0.0005) compared to subjects without CFLD (from 310 to 279 U/L, P 5 0.06) (Fig. 4) . Next, mean platelet counts over the last 2 years of follow-up were compared in subjects with and without CFLD by the new criteria between subjects who were alive and deceased by the end of the study period. In this analysis, deceased subjects with CFLD had significantly lower mean platelet counts than those who were alive with CFLD (143 versus 258 U/L, P 5 0.004) and those who were deceased without CFLD (143 versus 327 U/L, P 5 0.006) (Fig. 4) . However, there were no significant differences in mean platelet counts between subjects who were dead and alive without CFLD.
Discussion
In this prospective, natural history study of patients with genetically confirmed CF followed for up to 38 years, we demonstrate that adult-onset CFLD can have an impact on morbidity. Additionally, we demonstrate that a composite system using routine serum laboratory measurements, radiologic imaging, VCTE, and noninvasive fibrosis markers may have utility in identifying subjects with adult CFLD. In comparison to the widely used composite diagnostic algorithm for CFLD, (12) our new criteria captured an additional 25% (n 5 9) of patients with CFLD, in addition to demonstrating that those who died in the CFLD group had significantly lower platelet counts, which is a surrogate marker of end-stage liver disease with portal hypertension.
One of the major strengths of this study is the long duration of follow-up, which allowed for the identification of individuals who developed CFLD in adulthood. While CFLD in childhood is well characterized, adultonset CFLD has not generally been an active area of research concentration. Despite this, several major pieces describing the incidence of CFLD have alluded to the possibility of a second wave of liver disease in adulthood. For example, Colombo et al. (9) identified fewer than 4 adult subjects with CFLD with 1 diagnosed at age 28, and another large multinational study excluded 4 subjects from the analysis as they met criteria for CFLD at >30 years of age. (26) In our cohort, we describe that adult-onset CFLD occurred at a median age of 37 years in the absence of any biochemical or radiological evidence of liver disease during childhood. Additional studies are needed for further understanding and characterization as patients with CF are living longer lives with improved medical management.
Another important finding in this study is the demonstration of the utility of incorporating VCTE (FibroScan) and noninvasive fibrosis markers into a diagnostic algorithm for CFLD. Recently, increasing evidence has suggested the potential utility of FibroScan in the detection of pediatric CFLD, (27) (28) (29) (30) (31) with only a few studies in adults. (11, 32) This study adds to the growing body of evidence that VCTE may have utility in clinical practice in adult patients with CF. This is timely given that the FibroScan is approved by the US Food and Drug Administration for clinical use, which has resulted in increased availability in many advanced medical centers that routinely provide care to CF patients. Similarly, studies evaluating noninvasive fibrosis markers (specifically APRI and FIB-4) have solely been performed in children with CFLD. (26, 33) In this study, with the long duration of follow-up, we were able to expand on the experience of these biomarkers in pediatrics in addition to demonstrating their utility in identifying adults who develop CFLD. Taken together, by incorporating these biomarkers with routinely available serologic testing and radiologic imaging, we were able to incorporate simple tests to identify 25% more patients with CFLD compared to well-known and widely used historical criteria that have been essential to the CF field. (12) However, further experience is needed with these criteria in other CF cohorts prior to widespread application.
In the longitudinal evaluation of CF patients in our cohort, we identified that, compared to patients without CFLD, patients with CFLD demonstrated significant declines in platelet counts by the end of the follow-up period. Additionally, subjects with CFLD who died during the follow-up period had lower platelet counts than subjects alive with CFLD and deceased without CFLD. The demonstration of declining platelet counts, while not previously described in CFLD, is an important finding that has been described in various liver diseases ranging from cirrhosis-related liver diseases to noncirrhotic portal hypertension. In chronic hepatitis C, platelets have been described to decline with advancing disease even prior to reaching cirrhosis (34) with improvement after sustained viral eradication even at stages prior to cirrhosis. (35) In noncirrhotic portal hypertension, the declining platelet counts over time was associated with mortality. (25) Thus, the clinical utility of a declining platelet count over time may have the ability to serve as an "early warning" sign suggesting the evolution of liver disease in CF and should be explored further.
Finally, we identified that the pathogenesis of CFLD in adulthood may not be entirely due to cirrhosis-related liver diseases as it is often described in pediatric patients. This finding is similar to other systemic diseases where improved survival has revealed the emergence of other forms of liver disease, including those from the noncirrhotic portal hypertension spectrum. (36) (37) (38) In our cohort, one subject with portal hypertension and variceal bleeding was found to have NRH on liver biopsy. This finding not only expands on the solitary description of CFLD-NRH in the literature but also explains some of the potential diagnostic difficulties in CFLD where ALP has been reported to be the isolated abnormal liver test in 25% of NRH cases. (39) (40) (41) (42) Because NRH has been associated with chronic drug-induced liver injury from long-standing antibiotic use, as often seen in CF, it is possible that more cases of NRH may come to light with more experience in adult CFLD. (43) This study, while strong for the duration of followup to demonstrate the evolution of a second wave of liver disease in CF, is limited by the small number of patients followed, along with the fact that it was performed at a single center. These aspects may limit the generalizability of the findings, particularly with the effects on mortality. Further studies are needed in additional cohorts to expand the experience of adult CFLD and the utility of noninvasive biomarkers for the diagnosis of adult CFLD. Additionally, only two thirds of the subjects had FibroScan measurements performed, which were all performed in adulthood. This limitation is due to the fact that FibroScan was not performed at the NIH Clinical Center prior to 2007 and was not available before 2003. (44) As experience expands with VCTE in adults with CF, reporting of long-term FibroScan experience may enhance the ability to detect CFLD early. Finally, the lack of liver histology in each subject is a relative limitation of this study. However, it should be noted that the CFLD field has acknowledged the significant limitations of liver histology in CF given the often patchy histologic nature of liver disease in these subjects. Nevertheless, the potential implications from this study remain true, and the findings seem worthy of further exploration.
In summary, our study suggests that adult-onset CFLD may be more prevalent than previously described and that a second wave of liver disease with impact on mortality exists in CF. Through use of routine biomarkers consisting of standard liver tests, radiologic imaging, noninvasive fibrosis markers, and VCTE in an algorithmic fashion, the identification of adult CFLD is possible. Early identification of adult CFLD may help to prevent or delay morbidity and mortality. Further evaluation of other CF cohorts should be performed for continued characterization of adult CFLD and validation of these new diagnostic criteria.
